Is palmitoyl tripeptide-1 FDA-approved, and what does the research show?

What is palmitoyl tripeptide-1?

Palmitoyl tripeptide-1 is a cosmetic peptide built in a laboratory from three amino acids ¹. The three are glycine, histidine and lysine, written GHK ¹. The Cosmetic Ingredient Review, an expert panel funded by the cosmetics industry's trade association, describes GHK as "a fragment of type I collagen," the skin's main structural protein ¹,⁷. Palmitic acid, a 16-carbon fatty acid, is attached to one end to help the peptide cross the skin's outer layer ². The result is written pal-GHK ².

Until 2013 the ingredient was listed as palmitoyl oligopeptide ¹. The cosmetics industry's naming reference, the International Cosmetic Ingredient Dictionary and Handbook, retired that name as "vague," because it stood for either of two different peptides ¹. The industry's ingredient dictionary lists its function as a skin conditioning agent ¹. It is sold paired with palmitoyl tetrapeptide-7 as the blend Matrixyl 3000 ⁸,².

Is palmitoyl tripeptide-1 FDA-approved?

No. FDA approves no cosmetic ingredient before sale other than color additives ³. FDA's page on its authority over cosmetics says that "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives" ³. Under that law the makers and sellers of a cosmetic "have a legal responsibility to ensure the safety of their products" ³. Nothing in the law obliges them to send FDA that safety data ³.

Palmitoyl tripeptide-1 is not FDA-approved as a drug either ⁴. Drugs@FDA, FDA's database of approved drug products, lists no palmitoyl tripeptide-1, pal-GHK or palmitoyl oligopeptide product as of November 9, 2026 ⁴. FDA decides whether a product is a cosmetic or a drug by its intended use, which it reads from the claims made for it, its reputation and its ingredients ⁹.

FDA's page on anti-aging products says that "if a product is intended, for example, to remove wrinkles or increase the skin's production of collagen, it's a drug or a medical device" ¹⁰. If a product is intended "to make lines and wrinkles less noticeable, simply by moisturizing the skin, it's a cosmetic" ¹⁰. A cream with this ingredient therefore reaches you without any FDA check of its safety or effect before sale ³. A claim that it raises collagen is a drug claim in FDA's reading, wherever the claim is made ⁹,¹⁰.

The Modernization of Cosmetics Regulation Act of 2022 added a recall power for cosmetics ¹¹. It applies when there is "a reasonable probability" that a cosmetic is unsafe or mislabeled, in the law's terms adulterated or misbranded, and that its use "will cause serious adverse health consequences or death" ¹¹. FDA now "has the authority to order a mandatory recall if the responsible person," the company named on the label, "refuses to do so voluntarily" ¹¹.

The Cosmetic Ingredient Review issued a final report on this ingredient on June 30, 2014 ¹. Its expert panel concluded that the ingredients in that report, palmitoyl tripeptide-1 among them, are "safe in the present practices of use and concentration in cosmetics" ¹. The panel is not FDA, and its conclusion is not an approval.

See the FDA status of every peptide, updated weekly.

How does palmitoyl tripeptide-1 work?

The proposed mechanism is a signal to the skin's collagen-making cells. GHK is described as a signal peptide, a short sequence that prompts skin cells to make their supporting proteins ⁵,². In skin, GHK itself raises the production of collagen, elastin and glycosaminoglycans, the sugars that hold water in the skin ².

Shown in cells: the panel's report cites a 2000 paper by Sederma, the ingredient's maker ¹. The report records a strong signal of collagen synthesis from palmitoyl tripeptide-1 in human fibroblasts, the cells that build collagen ¹. For a cream, the mechanism remains a hypothesis: a 2024 review found no cellular or clinical study of pal-GHK's own anti-wrinkle effect in the published literature ².

Whether the peptide reaches those cells is unsettled. In a laboratory test on a synthetic epidermis, 4.61 percent of applied pal-GHK crossed in 24 hours, against 2.53 percent of plain GHK ⁸,². In 2026, a study applied a serum containing the Matrixyl 3000 blend to the skin of three volunteers ¹². It detected pal-GHK through every layer of the stratum corneum, the skin's outer layer, sitting between the cells rather than inside them ¹². A 2022 review of skin permeability concluded that most anti-wrinkle peptides "might not reach their targets in the skin at right concentrations" without enhancement ⁸.

What does the research show?

Studied in people: the panel summarized two small studies by Sederma, the ingredient's maker, from papers published in 2000 ¹. A vehicle-controlled test, in which the comparison is the same cream without the peptide, enrolled 15 women aged 44 to 59 ¹. They applied a cream with 3 parts per million of the peptide around the eyes for four weeks ¹. The panel reports decreases of 39 percent in wrinkle length, 23 in depth and 17 in roughness, analyzed against day 0 and the vehicle ¹. In 23 women, four weeks of the peptide at 4 parts per million raised skin thickness by about 4 percent against the vehicle alone ¹.

The panel's report includes a two-month half-face study, reported in the maker's own synopsis, of Matrixyl 3000 at 3 percent in a cream ¹. The comparison was a placebo cream, the same cream without the blend, on the other half of the face ¹. It enrolled 24 volunteers with a mean age of 56.1 years ¹. The blend side showed less deep wrinkling and roughness and more elasticity against day 0 ¹. The placebo side did not change significantly, and the report gives no comparison of the two sides ¹.

Studied in people: in a 2023 study, 32 women aged 20 to 45 completed 28 days of a multi-peptide eye serum with no comparison group ⁵. The serum carried 4 percent Matrixyl 3000 alongside 10 percent acetyl hexapeptide-8, another cosmetic peptide, and 2 percent of a third peptide blend ⁵. Nothing in its result is this ingredient's alone ⁵. Wrinkle number fell by 33.29 percent and wrinkle volume by 12.69 percent from baseline, while hydration and elasticity did not change significantly in the paper's table, though its abstract says they "increased continuously" ⁵. A cosmetics company, Dingmageili Biotechnology, funded the study and employs two of its authors, and the serum came from another company ⁵.

Studied in people, eye-cream trial: 37 women aged 20 to 55 used a cream for twelve weeks on one side of the face ⁶. The cream carried palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 and two other active ingredients ⁶. Against the untreated side, hydration rose 28.12 percent, elasticity 18.81 percent and ultrasound collagen density 54.99 percent ⁶. The untreated side of the face was the comparison, though the authors themselves write that the study "did not include a control or placebo group" ⁶. Its first authors work for the cream's maker ⁶.

In 2026, a randomized, single-blind trial paired the peptide at night with the plant compound baicalin by day ¹³. Single-blind means that either the participants or the assessors, not both, were kept unaware of the treatment. Thirty women used the two creams for eight weeks ¹³. The depth of the nasolabial folds, the lines from nose to mouth, fell 36.35 percent from baseline, a result of the pairing, not the peptide ¹³.

A 2024 review of GHK and its derivatives found "a surprising absence of clinical studies" of pal-GHK ². Beyond the two 2000 studies the panel cited, every later human study pairs the peptide with other ingredients or tests a finished product ⁵,⁶,¹³.

What are the side effects?

In the panel's report, a mixture holding 1,000 parts per million of the peptide went through a 48-hour patch test on 10 adults ¹. A patch test holds the product against the skin under a sealed patch, and this one caused no irritation ¹. In rabbits, a 100 parts per million mixture was a slight eye irritant and caused slight redness on two of three animals' skin ¹.

A repeated insult patch test applies the mixture to the same skin again and again to look for allergy ¹. In a patch test that 52 of 57 people aged 16 to 79 completed, reactions were scored from barely perceptible to moderate ¹. The report calls these transient, low-level responses clinically insignificant and finds no "clinically significant potential for skin irritation or sensitization," meaning allergy ¹.

The human studies of products containing it reported no adverse skin reactions ⁵,⁶,¹³. That covers 32 women on the serum for 28 days, 37 on the eye cream for twelve weeks and 30 in the eight-week trial ⁵,⁶,¹³. The 2024 review states that "no studies have been published on the possible side effects of these peptides" ². The panel's safety conclusion is "in the present practices of use and concentration," which it recorded as typically below 10 parts per million and at most 10 parts per million ¹.

In sport

Palmitoyl tripeptide-1 is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ¹⁴.

What JumpstartMD offers

JumpstartMD does not prescribe palmitoyl tripeptide-1. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.